Tissue-specific genes as an underutilized resource in drug discovery

Area of Science:

• Pharmacogenomics
• Drug Discovery
• Genetics

Background:

• Tissue-specific genes are hypothesized as ideal drug targets for enhanced safety.
• Historically, tissue-specific targets have shown success and are overrepresented in marketed non-oncology drugs.

Purpose of the Study:

• To evaluate the clinical trial success of tissue-specific genes as drug targets.
• To analyze the properties of tissue-specific genes and their relationship with drug efficacy.
• To explore new avenues for identifying tissue-specific drug targets.

Main Methods:

• Comparative analysis of tissue-specific genes and known drug targets.
• Assessment of clinical trial data (Phase 1 and 2).
• Evaluation of gene properties like evolutionary conservation and network centrality.

Main Results:

• The intuitive notion of tissue-specific genes yielding better safety in early trials is not supported by current data.
• Tissue-specificity can correlate with drug efficacy through indirect (Mendelian disease genes) or direct (network centrality) mechanisms.
• Reduced evolutionary conservation of tissue-specific genes poses a challenge for drug development.

Conclusions:

• Despite challenges, opportunities for identifying effective tissue-specific drug targets remain.
• Novel models with reduced evolutionary gaps may aid in developing drugs for tissue-specific targets.
• Further research into the complex relationship between tissue-specificity and drug action is warranted.